FN Media Group Presents Microsmallcap.com Market Commentary
New York, NY – March 17, 2021 – What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Legalization efforts began with marijuana in 2018, creating a booming market for investors. Now, the psychedelics market is in the spotlight, with states across America looking to decriminalize psychedelic mushrooms. California is the latest state inching closer to decriminalizing shrooms, with a third city now pushing for legalization thanks to ongoing research into the benefits of psychedelics in the treatment and management of mental illnesses. Investors are taking note of these developments, creating an exciting opportunity for companies like Numinus Wellness Inc. (TSXV:NUMI), Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (NEO:MMED), Cybin Inc. (NEO:CYBN), COMPASS Pathways plc. (NASDAQ:CMPS), and Atai Life Sciences N.V. (NASDAQ:ATAI).
Numinus Takes Steps to Position Itself as a Leader in the Psychedelic Market
Numinus Wellness Inc. (TSXV:NUMI) is a mental health and wellness company dedicated to providing access to safe and evidence-based psychedelic therapies that aim to heal rather than manage symptoms of depression, anxiety, trauma, substance abuse, and pain. As the first Canadian public company to receive a dealer’s licence from Health Canada to produce and extract psilocybin from mushrooms and the first to complete a legal harvest of psilocybe mushrooms, Numinus Wellness Inc. is positioned at the forefront of the psychedelic medicine movement.
On July 12, 2021, Numinus Wellness announced that Health Canada has given the green light to the MAPS-sponsored open-label study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The study is being pursued in collaboration with a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of MDMA-assisted therapy training programs, treatment protocols and research. Study preparations are now transitioning into the final stages of training staff, importing medication and obtaining ethical approval to allow the recruitment of participants. This study advanced through the pre-implementation stage at Numinus’ Vancouver clinic and has now received the required federal regulatory approval.
“We are thrilled that Health Canada has issued its No Objection Letter allowing this important study to proceed and, in doing so, potentially advance Canada toward a legal, regulated system for MDMA-assisted therapy,” said Numinus CEO Payton Nyquvest. “At Numinus, we are focused on expanding patient access to psychedelic-assisted therapies such as MDMA for PTSD, and we are gratified that our study will provide safety and outcome data to regulators to support integration of this treatment into mainstream mental health care.”
Days earlier, Numinus announced the acquisition of the Neurology Centre of Toronto (NCT), a fully operational neurology centre with 13 doctors, 8 allied health staff, nurse practitioners and physician assistants. NCT’s expertise in clinical neurology and associated mental health disorders will be integrated with Numinus’ leadership in psychedelic-assisted psychotherapy to establish the field of psychedelic neurology, to develop strategies and treatments for those with select neurological and concurrent disorders. The acquisition of this revenue-generating centre offers Numinus additional expertise and access to NCT’s information technology-based virtual rapid access care model, which will help streamline and scale pathways for patients to access psychedelic-assisted psychotherapies.
Numinus Wellness Inc. also recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery of several psychedelics including ketamine and Lysergic acid diethylamide (LSD). The company also closed an impressive upsized $40 million bought deal financing and announced its plans to expand its state-of-the-art psychedelics research laboratory, which will be equipped with $1.2 million in new equipment.
Numinus Wellness closed the second quarter with $65 million in cash, providing the company with the capital to bolster its leadership team, file a patent application with the United States Patent and Trademark Office for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy, and launch a Phase 1 clinical trial of natural psilocybin mushroom extraction in partnership with KGK Science.
These Companies are Seeking to Transform Mental Health with Psychedelic Therapies
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (NEO:MMED) is a clinical-stage psychedelic medicine biotech company that develops psychedelic medicines and therapies for the treatment of mental illness and addiction. The company recently received Type C meeting responses from the FDA regarding its Project Lucy. Afterward, the company intends to submit its IND in Q3 and begins the phase 2b clinical trials in Q4 2021. Mind Medicine is also collaborating with Nextage Therapeutics in a program to optimize the delivery of psychedelic drug candidates using the Brain Targeting Liposome System to mitigate some serious side effects that come with orally administered psychedelics. The company also collaborated with Swiss lab Liechti Lab in the publication of the first pharmacogenetic data on LSD to help in dose selection based on individual factors.
Cybin Inc. (NEO:CYBN) is another company active in the psychedelic space. The biotechnology company focused on developing psychedelic therapies announced that its wholly-owned subsidiary Adelia Therapeutics Inc. achieved part of its earn-out milestones after positive pre-clinical results. The completion of these milestones advances the company’s portfolio of differentiated psychedelic-based therapies for different mental health conditions. Cybin also released its financial results for the FY ended March 31, 2021, which show cash and cash equivalents of C$64,026,000 as of March 31, 2021. The company boasts an expanded IP portfolio with 12 patent filings, including an international patent application, which gives Cybin potential patent coverage in 153 counties.
COMPASS Pathways plc. (NASDAQ:CMPS) is another company positioned to benefit from the boom in the psychedelics market space. COMPASS recently completed the administration to a target of 216 patients in a phase 2b clinical trial. The study is investigating the safety and efficacy of psilocybin therapy by comparing 25 mg and 10 mg of COMP360 psilocybin with 1 mg administered together with psychological support from trained therapists. Compass Pathways expects to finalize all psilocybin sessions by July 8, with the report data expected sometime in late 2021. COMP360, if approved, could receive up to 11 years of market exclusivity in the EU and US.
Atai Life Sciences (NASDAQ:ATAI) is another clinical-stage biopharmaceutical company that seeks to transform the treatment of mental health conditions using innovative psychedelic-based drugs. The company became the latest psychedelic company to go public, launching its IPO of 14,286,000 of its common shares on June 11, 2021, with the expected price of between $13 and $15 per common share. The company later upsized its IPO on June 17, 2021, offering 15,000,000 in the US for $15 per share.
Psychedelics are gaining mainstream acceptance as researchers, patients, and investors take note of their medical benefits. Companies like Numinus Wellness Inc. (TSXV:NUMI) are positioning themselves for this market opportunity.
For more information about Numinus Wellness Inc., click here.
Disclaimer: Microsmallcap.com (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Numinus Wellness
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
FN Media Group, LLC